Short report: Glucose-6-phosphate dehydrogenase deficiency A - Variant in febrile patients in Haiti

Tamar E. Carter*, Halley Maloy, Michael Von Fricken, Yves St. Victor, Jean R. Romain, Bernard A. Okech, Connie J. Mulligan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Haiti is one of two remaining malaria-endemic countries in the Caribbean. To decrease malaria transmission in Haiti, primaquine was recently added to the malaria treatment public health policy. One limitation of primaquine is that, at certain doses, primaquine can cause hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd). In this study, we genotyped two mutations (A376G and G202A), which confer the most common G6PDd variant in West African populations, G6PDd A-. We estimated the frequency of G6PDd A-in a sample of febrile patients enrolled in an on-going malaria study who represent a potential target population for a primaquine mass drug administration. We found that 33 of 168 individuals carried the G6PDd A-Allele (includes A-hemizygous males, A-homozygous or heterozygous females) and could experience toxicity if treated with primaquine. These data inform discussions on safe and effective primaquine dosing and future malaria elimination strategies for Haiti.

Original languageEnglish
Pages (from-to)412-414
Number of pages3
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume91
Issue number2
DOIs
StatePublished - Aug 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Short report: Glucose-6-phosphate dehydrogenase deficiency A - Variant in febrile patients in Haiti'. Together they form a unique fingerprint.

Cite this